keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/29741110/vaginal-health-insights-views-attitudes-viva-latam-results-from-a-survey-in-latin-america
#1
R E Nappi, N R de Melo, M Martino, C Celis-González, P Villaseca, S Röhrich, S Palacios
OBJECTIVE: To investigate awareness in Latin America, knowledge of postmenopausal vaginal atrophy was evaluated in a sample of women from this region. METHODS: A total of 2509 postmenopausal women aged 55-65 years, resident in Argentina, Brazil, Chile, Colombia and Mexico, completed a structured online questionnaire. RESULTS: Over half the surveyed population (57%) reported experiencing symptoms of vaginal atrophy. Only 6% of the overall cohort attributed symptoms of vaginal atrophy directly to the condition, and 71% did not consider the condition to be chronic, resulting in many women not accessing effective therapy...
May 9, 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29738415/efficacy-of-injecting-platelet-concentrate-combined-with-hyaluronic-acid-for-the-treatment-of-vulvovaginal-atrophy-in-postmenopausal-women-with-history-of-breast-cancer-a-phase-2-pilot-study
#2
Barbara Hersant, Mounia SidAhmed-Mezi, Yazid Belkacemi, Franklin Darmon, Sylvie Bastuji-Garin, Gabrielle Werkoff, Romain Bosc, Jeremy Niddam, Oana Hermeziu, Simone La Padula, Jean Paul Meningaud
OBJECTIVE: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer. METHODS: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of <15 on the Gloria Bachman Vaginal Health Index (VHI) comprised of five items including: vaginal pH, elasticity, fluid volume (secretions), epithelial integrity, and moisture...
May 7, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29726916/treatment-to-external-labia-and-vaginal-canal-with-co2-laser-for-symptoms-of-vulvovaginal-atrophy-in-postmenopausal-women
#3
Julene B Samuels, Martin A Garcia
Background: Increasingly, women have sought alternatives to traditional options (lubricants, estrogen products, and hormone replacement therapy) for unwelcome vaginal changes of menopause. Objectives: This study evaluated whether a series of three monthly fractional CO2 laser treatments significantly improves and maintains vaginal health indices of elasticity, fluid volume, pH level, epithelial integrity, and moisture. Self-reported symptoms of vaginal atrophy were also measured...
April 13, 2018: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29696061/effect-of-fennel-vaginal-cream-on-sexual-function-in-postmenopausal-women-a-double-blind-randomized-controlled-trial
#4
Parvin Abedi, Mahin Najafian, Masumeh Yaralizadeh, Foroogh Namjoyan
Objective: The aim of this study was to assess the effect of fennel on sexual function in postmenopausal women. It was a randomized controlled trial in 60 postmenopausal women with sexual dysfunction who were randomly assigned to two groups receiving either fennel vaginal cream (n=30) or placebo (n=30). Vaginal atrophy in the women was assessed using symptoms such as pallor, dryness, dyspareunia, itching and burning. The pH of the vagina and cytology of the vaginal mucosa were also measured at baseline and 8 weeks after the intervention...
January 2018: Journal of Medicine and Life
https://www.readbyqxmd.com/read/29680080/no-358-intravaginal-laser-for-genitourinary-syndrome-of-menopause-and-stress-urinary-incontinence
#5
Jens-Erik Walter, Annick Larochelle
OBJECTIVE: This technical bulletin reviews the evidence relating to risks and benefits of using intravaginal laser technology in the management of genitourinary syndrome of menopause and stress urinary incontinence. INTENDED USERS: Gynaecologists, urogynaecologists, urologists, and other health care professionals who assess, counsel, and provide care for women with genitourinary syndrome of menopause and stress urinary incontinence. TARGET POPULATION: Adult women with genitourinary syndrome of menopause and stress urinary incontinence seeking complementary or alternative treatment options to topical estrogen, non-hormonal vaginal moisturizers, physiotherapy, intravaginal devices, and surgery...
April 2018: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/29677538/improvement-effects-of-a-mixed-extract-of-flowers-of-pueraria-thomsonii-benth-and-peels-of-citrus-unshiu-markovich-on-postmenopausal-symptoms-of-ovariectomized-mice
#6
Na-Ra Han, Sun-Young Nam, Sungwei Hong, Hee-Yun Kim, Phil-Dong Moon, Hyeong-Jin Kim, Hosong Cho, Boyoung Lee, Hyung-Min Kim, Hyun-Ja Jeong
BACKGROUND: Menopausal hot flushes occur frequently in postmenopausal women. In the present study, we investigated a regulatory effect of a mixed extract of flowers of Pueraria thomsonii Benth. and peels of Citrus unshiu Markovich (PCE17), an extract of flowers of Pueraria thomsonii Benth. (PE), an extract of peels of Citrus unshiu Markovich (CE), a mixture of tectorigenin 7-O-xylosylglucoside, tectoridin, and tectorigenin (Tec, the active compounds of PE), and hesperidin (Hes, an active compound of CE) on menopausal hot flushes...
April 17, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29667744/intraurethral-erbium-yag-laser-for-the-management-of-urinary-symptoms-of-genitourinary-syndrome-of-menopause-a-pilot-study
#7
Adrian Gaspar, Sandra Maestri, Joaquin Silva, Hugo Brandi, Daniel Luque, Neža Koron, Zdenko Vižintin
OBJECTIVES: Genitourinary syndrome of menopause (GSM) combines the conditions of vulvovaginal atrophy (VVA) and urinary tract dysfunction, which is a result of urethral atrophy. There are several treatment methods available for the management of vulvovaginal symptoms of GSM, whereas urinary tract dysfunction often remains overlooked and undertreated. The objective of this pilot study was to assess the safety and efficacy of intraurethral Er:YAG laser treatment of urinary symptoms of GSM...
April 18, 2018: Lasers in Surgery and Medicine
https://www.readbyqxmd.com/read/29603520/effect-of-pomegranate-extract-on-vagina-skeleton-metabolic-and-endocrine-profiles-in-an-ovariectomized-rat-model
#8
Isik Kaban, Alpaslan Kaban, Aysun F Tunca, Nurettin Aka, Hacer Kavak, Fugen Akar
AIM: Many women need estrogen therapy because of menopausal complaints. It is suggested that pomegranate plant has estrogenic effect. Aim of the study was to examine the effects of pomegranate seed extract on menopausal changes. METHODS: This study was conducted in an experimental environment with 23 Wistar Albino genus female rats. Sixteen rats were divided into two groups after ovariectomy. One group (SG) was fed with standard food and the pomegranate extract was added to drinking water of the other group (PG)...
March 30, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29578197/immunohistochemical-expression-of-hypoxia-inducible-factor-1%C3%AE-in-stromal-cells-of-vaginal-tissue-in-post-menopausal-women-with-pelvic-organ-prolapse
#9
Ivana Alujević Jakus, Dora Jakus, Nađa Aračić, Ivica Stipić, Katarina Vilović
Background & objectives: Pelvic organ prolapse (POP) is a common medical condition that affects adult women of different ages. The support of a normal pelvic floor is the result of complex interactions between ligaments, muscles, connective tissue and vaginal walls. Hypoxia and oxidative stress can reduce protein synthesis in the pelvic muscles that may contribute to muscular atrophy. Hypoxia-inducible factor-1α (HIF-1α) is a transcriptional activator which, expressed in response to hypoxia, activates a number of genes involved in cellular response to hypoxia...
November 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/29566925/genital-diseases-in-the-mature-woman
#10
Natalie Matthews, Vivian Wong, Joe Brooks, George Kroumpouzos
Vulvovaginal conditions are common in mature women. This reflects age-related changes in immunity and skin barrier function of vulvovaginal tissues. Vaginal atrophy is commonly complicated by dryness and inflammation, which makes postmenopausal atrophic vaginitis a virtually ubiquitous condition. The differential of vaginitis includes inflammatory, infectious, and malignant diseases, plus drug hypersensitivity. Atrophic vaginitis is treated with estrogen replacement therapy. Vulvovaginal malignant melanoma occurs predominantly in postmenopausal women and carries a poor prognosis...
March 2018: Clinics in Dermatology
https://www.readbyqxmd.com/read/29553288/the-european-vulvovaginal-epidemiological-survey-eves-prevalence-symptoms-and-impact-of-vulvovaginal-atrophy-of-menopause
#11
S Palacios, R E Nappi, N Bruyniks, M Particco, N Panay
OBJECTIVES: The primary objective of the European Vulvovaginal Epidemiological Survey (EVES) was to assess, at a country level, the prevalence of postmenopausal women with vulvovaginal atrophy (VVA) confirmed by gynecological clinical assessment among all postmenopausal women attending menopause centers. METHOD: Women aged 45-75 years old with their last menstrual period more than 12 months before and who attended menopause or gynecology centers were included...
March 19, 2018: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/29509598/vaginal-ph-a-simple-assessment-highly-correlated-with-vaginal-morphology-and-symptoms-in-postmenopausal-women
#12
Kelly M Tucker, Keshav Godha, Sebastian Mirkin, David F Archer
OBJECTIVE: The aim of the study was to determine the utility of vaginal pH as a marker of menopause and vulvar and vaginal atrophy (VVA) before and after local estrogen treatment. METHODS: Vaginal pH was determined using standard pH paper strips in two clinical trials involving postmenopausal women with signs and symptoms of VVA evaluated before and after intervention with vaginal estradiol in softgel capsules. The utility of vaginal pH was evaluated as a screening method for VVA due to menopause and correlations were analyzed between vaginal pH and VVA symptoms, physical changes, and maturation of the vaginal epithelium...
March 5, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29502137/effectiveness-of-the-remeex-system%C3%A2-in-colombian-women-with-recurrent-stress-urinary-incontinence-or-intrinsic-sphincter-deficiency
#13
Mauricio Plata, Daniela Robledo, Alejandra Bravo-Balado, Juan Carlos Castaño, Catalina Osorio, Milton Salazar, Juan Guillermo Velásquez, Carlos Gustavo Trujillo, Juan Ignacio Caicedo, Juan Guillermo Cataño
INTRODUCTION AND HYPOTHESIS: We report our experience with the Remeex system™ in women with recurrent stress urinary incontinence (SUI) or intrinsic sphincter deficiency (ISD). METHODS: A multicenter retrospective study was conducted in women who underwent an adjustable sling procedure between 2011 and 2016. We used urodynamic studies (UDS) preoperatively and the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and cough stress test (CST) pre- and postoperatively...
March 3, 2018: International Urogynecology Journal
https://www.readbyqxmd.com/read/29487993/ablative-dual-phase-erbium-yag-laser-treatment-of-atrophy-related-vaginal-symptoms-in-post-menopausal-breast-cancer-survivors-omitting-hormonal-treatment
#14
A R Mothes, M Runnebaum, I B Runnebaum
PURPOSE: First evaluation of dual-phase vaginal Er:YAG laser to omit hormonal treatment for atrophy-related symptoms in post-menopausal breast cancer survivors following prolapse surgery. METHODS: Patients with a history of breast cancer at the time of surgery for pelvic organ prolapse were offered non-hormonal vaginal Er:YAG laser treatment when complaining of atrophy-related genitourinary syndrome of menopause. A single 10-min course of dual-phase protocol of pulsed Er:YAG laser (2940 nm, fractional ablative and thermal mode, fluence according to tissue thickness)...
May 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29463148/overactive-bladder-syndrome-treatment-with-ospemifene-in-menopausal-patients-with-vulvovaginal-atrophy-improvement-of-sexuality
#15
Michele Carlo Schiavi, Valentina Sciuga, Andrea Giannini, Flaminia Vena, Ottavia D'oria, Giovanni Prata, Chiara Di Tucci, Delia Savone, Natalia Aleksa, Carmela Capone, Daniele Di Mascio, Maria Letizia Meggiorini, Marco Monti, Marzio Angelo Zullo, Ludovico Muzii, Pierluigi Benedetti Panici
The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60 mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks...
February 20, 2018: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29462095/hormonal-metabolic-and-endometrial-safety-of-testosterone-vaginal-cream-versus-estrogens-for-the-treatment-of-vulvovaginal-atrophy-in-postmenopausal-women-a-randomized-placebo-controlled-study
#16
Tatiane Fernandes, Adriana O Pedro, Luiz F Baccaro, Lucia H Costa-Paiva
OBJECTIVE: The aim of the study was to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for the treatment of vaginal atrophy in postmenopausal women. METHODS: This was a randomized, placebo-controlled trial of 60 postmenopausal women aged 40 to 70 years at the Menopause Clinic of CAISM UNICAMP. Women were randomized into three vaginal treatment groups: estrogen, testosterone, or placebo. The treatment was applied 3 times a week for 12 weeks...
February 16, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29452786/preliminary-results-of-a-single-arm-pilot-study-to-assess-the-safety-and-efficacy-of-visnadine-prenylflavonoids-and-bovine-colostrum-in-postmenopausal-sexually-active-women-affected-by-vulvovaginal-atrophy
#17
Antonio Simone Laganà, Salvatore Giovanni Vitale, Lily Stojanovska, Irene Lambrinoudaki, Vasso Apostolopoulos, Benito Chiofalo, Laura Rizzo, Francesca Basile
This single-arm pilot study enrolled 47 post-menopausal women affected by vulvovaginal atrophy (VVA). The Vaginal Health Index Score (VHIS) was evaluated for all women and all completed the Female Sexual Function Index (FSFI) questionnaire at baseline (T0) and after 15 days of vaginal cream treatment with one application per day (T1). Following treatment there was a significant improvement in all VHIS parameters and total score (p < 0.0001). Similarly, there was a significant improvement on four FSFI domains (lubrication, orgasm, satisfaction and pain) and total score (p = 0...
March 2018: Maturitas
https://www.readbyqxmd.com/read/29438648/managing-menopausal-symptoms-after-cancer-an-evidence-based-approach-for-primary-care
#18
Jennifer L Marino, Helen C McNamara, Martha Hickey
Impaired ovarian function and menopausal symptoms are common after cancer treatment. Menopausal symptoms often occur at an earlier age in women with cancer, and may be more severe than in natural menopause; they may be the most persistent and troubling sequelae of cancer. A third of female patients with cancer report dissatisfaction with the quality and length of physician-patient discussions about reproductive health, including menopause. Systemic menopausal hormone therapy is the most effective treatment for menopausal symptoms, but it is not suitable for all patients after cancer - where it is unsuitable, alternative effective non-hormonal treatments are available...
February 19, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29424920/menopause-new-frontiers-in-the-treatment-of-urogenital-atrophy
#19
G A Casarotti, P Chiodera, C Tremolada
OBJECTIVE: Urogenital atrophy is a degenerative process that may occur during menopause causing debilitating disorders and painful symptomatology. Estrogen therapy slows the onset of atrophy, but it requires ongoing therapy to maintain its effectiveness. To mitigate the degenerative evolutions associated with menopause, patients may benefit from new therapeutic approaches, such as the use of mesenchymal stem cells. Among the many sources, the adipose tissue is considered one of the smartest, due to its abundance and easy access...
January 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29411644/genitourinary-syndrome-of-menopause-prevalence-and-quality-of-life-in-spanish-postmenopausal-women-the-genisse-study
#20
E Moral, J L Delgado, F Carmona, B Caballero, C Guillán, P M González, J Suárez-Almarza, S Velasco-Ortega, C Nieto
OBJECTIVE: To determine the prevalence of genitourinary syndrome of menopause (GSM) and urogynecological conditions associated with menopause, and to evaluate the impact of GSM on quality of life in a cohort of Spanish postmenopausal women. METHODS: Multicenter, cross-sectional, and observational study involving 430 women. RESULTS: The prevalence of GSM was 70%. GSM was diagnosed in 60.2% of women with no known diagnosis of vulvovaginal atrophy or GSM...
April 2018: Climacteric: the Journal of the International Menopause Society
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"